Posted by Michael Wonder on 07 Jan 2023
Novan submits new drug application to the US FDA for berdazimer (SB206) 10.3% topical gel for the treatment of molluscum contagiosum
6 January 2023 - Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by the FDA and under standard review timelines.
Novan announced today that the Company has submitted a new drug application to the US FDA seeking marketing approval for berdazimer (SB206) 10.3% topical gel for the topical treatment of molluscum contagiosum.
